Back to top
more

Karyopharm Therapeutics (KPTI)

(Delayed Data from NSDQ)

$7.25 USD

7.25
486,661

+0.04 (0.55%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $7.26 +0.01 (0.14%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (94 out of 243)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Brokerage Reports

Research for KPTI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Karyopharm Therapeutics Inc. [KPTI]

Reports for Purchase

Showing records 1 - 20 ( 403 total )

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 1

03/13/2026

Industry Report

Pages: 44

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 6

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 2

03/04/2026

Company Report

Pages: 4

Credit Agreement Amendment Provides Additional Flexibility; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 3

02/18/2026

Company Report

Pages: 4

Top-Line SENTRY Data Expected Next Month; 4Q25 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 4

11/04/2025

Company Report

Pages: 4

Top-Line SENTRY Data Expected in March 2026; 3Q25 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 5

10/13/2025

Company Report

Pages: 4

Strategic Financing Extends Runway Beyond Top-Line Results From SENTRY Trial; Upgrading to Buy With $15 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 6

07/16/2025

Company Report

Pages: 4

Financial Overhang Raises Solvency Concerns; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 7

07/11/2025

Company Report

Pages: 31

Significant Near-Term Catalysts; Assuming Coverage With a Buy and $27 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 75.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 8

02/26/2025

Company Report

Pages: 8

Model Update Following Reverse Stock Split

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 9

02/20/2025

Company Report

Pages: 8

4Q24 Results; Topline Data From Phase 3 SENTRY Trial in MF Expected 2H25; Phase 3 Endometrial Cancer Trial Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 10

01/15/2025

Company Report

Pages: 6

Xpovio 2024 Revenue Preannounced; Updating Model

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 11

11/22/2024

Industry Report

Pages: 43

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended November 15

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 12

11/05/2024

Company Report

Pages: 8

3Q24 Results; Topline Phase 3 Readout for Xpovio in Combination With Jakafi for Myelofibrosis Patients Expected 2H25

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 13

10/31/2024

Company Report

Pages: 8

Co-Primary Endpoint of Phase 3 SENTRY Study Changed to Absolute Total Symptom Score From TSS50

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 14

08/07/2024

Company Report

Pages: 6

2Q24 Results; Xpovio Sales Beat Expectations; Lower End of Guidance Range Raised for 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 15

06/28/2024

Company Report

Pages: 7

Model Update; Lowering PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 16

06/03/2024

Company Report

Pages: 6

Solid Update From SIENDO Study in TP53 Wild-Type Endometrial Cancer Patients Presented at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 17

05/09/2024

Company Report

Pages: 6

1Q24 Results; All Eyes on Three Pivotal Phase 3 Studies Anticipated to Read Out in 2025

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 18

03/01/2024

Company Report

Pages: 6

4Q23 Results; Data From Three Phase 3 Pivotal Studies Expected in 2025

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 19

01/09/2024

Company Report

Pages: 6

FY23 Preliminary Revenues Disappoint, But Focus Should be on New Indications in the Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 20

12/29/2023

Company Report

Pages: 4

Dropping Coverage

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party